{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:05:36Z","timestamp":1790798736196,"version":"4.1.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>\n                    Venetoclax is a selective BCL-2 inhibitor that has transformed the treatment landscape for elderly and unfit patients with acute myeloid leukemia (AML). Its use has also been progressively extended to include\n                    <jats:italic>TP53<\/jats:italic>\n                    -mutated AML based on clinical outcomes comparable to other available standards of care. However,\n                    <jats:italic>TP53<\/jats:italic>\n                    -mutated AML is associated with high rates of primary and acquired resistances to venetoclax combinations, which have not afforded any meaningful gains to overall survival. The main causes for these limitations include profound genomic instability, loss of p53 pleotropic function, an immunosuppressive and exhausted marrow microenvironment, a shift away from BCL-2 dependence, defects in the post-mitochondrial executioner phase of apoptosis, lineage plasticity and monocytic differentiation, upregulation of fatty acid metabolism, and BCL-2 family gene mutations. In the present review, we discuss the pathobiology of the BCL-2 family of proteins in\n                    <jats:italic>TP53<\/jats:italic>\n                    -mutated AML, mechanisms of venetoclax\/BCL-2 inhibitor resistance in this molecular subset, and emerging strategies to potentially overcome this deficiency to guide therapeutic management for a population of patients who are in critical need of progress.\n                  <\/jats:p>","DOI":"10.3389\/fcell.2026.1779094","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:56:17Z","timestamp":1773816977000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in TP53-mutated acute myeloid leukemia"],"prefix":"10.3389","volume":"14","author":[{"given":"Umar","family":"Iqbal","sequence":"first","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center","place":["Tampa, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center","place":["Tampa, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-025-02528-3","article-title":"Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed\/refractory acute myeloid leukemia","volume":"39","author":"Abedin","year":"2025","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","article-title":"Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia","volume":"102","author":"Aiba","year":"2023","journal-title":"Ann. Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid Neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2024-211845","article-title":"Single-cell multiomics unveils venetoclax-resistant monocytic differentiation and immune evasion in TP53 mutant AML clones","volume":"144","author":"Ayoub","year":"2024","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Medicine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41375-025-02662-y","article-title":"Resistance to targeted therapies in chronic lymphocytic leukemia: current status and perspectives for clinical and diagnostic practice: chronic lymphocytic leukemia","volume":"39","author":"Blombery","year":"2025","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leukemia & Lymphoma"},{"key":"B8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1182\/bloodadvances.2024014446","article-title":"Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia","volume":"9","author":"Brown","year":"2025","journal-title":"Blood Adv."},{"key":"B9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-015-0224-3","article-title":"ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development","volume":"8","author":"Cang","year":"2015","journal-title":"J. Hematology & Oncology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2020.11.013","article-title":"Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/1538-7445.am2025-594","article-title":"Lintuzumab-Ac225 has potent mutation agnostic antileukemic activity in preclinical models of AML","volume":"85","author":"Chin","year":"2025","journal-title":"Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1092734","article-title":"Direct activation of bax by p53 mediates mitochondrial membrane permeabilization and apoptosis","volume":"303","author":"Chipuk","year":"2004","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrc883","article-title":"The Bcl2 family: regulators of the cellular life-or-death switch","volume":"2","author":"Cory","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","article-title":"Mechanisms of BCL-2 family proteins in mitochondrial apoptosis","volume":"24","author":"Czabotar","year":"2023","journal-title":"Nat. Reviews Mol. Cell Biology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discovery"},{"key":"B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J. Hematol. & Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1721","DOI":"10.1038\/cddis.2015.97","article-title":"BCL-2 is dispensable for thrombopoiesis and platelet survival","volume":"6","author":"Debrincat","year":"2015","journal-title":"Cell Death & Disease"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1577908","DOI":"10.3389\/fonc.2025.1577908","article-title":"Factors affecting response and resistance to venetoclax in acute myeloid leukemia","volume":"15","author":"Diamantidis","year":"2025","journal-title":"Front. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. Journal Medicine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B22","first-page":"6","volume-title":"Results from paradigm-a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood","author":"Fathi","year":"2025"},{"key":"B23","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-025-01346-1","article-title":"Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms","volume":"15","author":"Gangat","year":"2025","journal-title":"Blood Cancer Journal"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/cam4.3665","article-title":"225Ac\u2010labeled CD33\u2010targeting antibody reverses resistance to Bcl\u20102 inhibitor venetoclax in acute myeloid leukemia models","volume":"10","author":"Garg","year":"2021","journal-title":"Cancer Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.3324\/haematol.2022.281396","article-title":"Molecular responses in decitabine-and decitabine\/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes","volume":"109","author":"Gruszczynska","year":"2024","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ijrobp.2004.10.008","article-title":"Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells","volume":"61","author":"Hara","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/348334a0","article-title":"Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death","volume":"348","author":"Hockenbery","year":"1990","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1002\/ajh.27180","article-title":"Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival","volume":"99","author":"Karrar","year":"2024","journal-title":"Am. Journal Hematology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1080\/10428194.2022.2084730","article-title":"Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis","volume":"63","author":"Khanam","year":"2022","journal-title":"Leukemia & Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world Health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discovery"},{"key":"B34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2019","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/10428194.2020.1719098","article-title":"Venetoclax in acute myeloid leukemia\u2013current and future directions","volume":"61","author":"Lachowiez","year":"2020","journal-title":"Leukemia & Lymphoma"},{"key":"B36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/jpm11060463","article-title":"Review of venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J. Personalized Medicine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc2297","article-title":"Diagnosing and exploiting cancer's addiction to blocks in apoptosis","volume":"8","author":"Letai","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1182\/blood-2024-210412","article-title":"TP53 mutations within T cells induce T-Cell exhaustion and functional impairment in TP53 mutant AML","volume":"144","author":"Li","year":"2024","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Mali","year":"2020","journal-title":"Haematologica."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1101\/2025.08.28.672283","article-title":"TP53 mutations drive therapy resistance via post-mitochondrial caspase blockade","author":"Mamdouh","year":"2025","journal-title":"bioRxiv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/s1097-2765(03)00050-9","article-title":"p53 has a direct apoptogenic role at the mitochondria","volume":"11","author":"Mihara","year":"2003","journal-title":"Mol. Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.27584","article-title":"Treatment of relapsed\/refractory AML\u2014Novel treatment options including immunotherapy","volume":"100","author":"Moore","year":"2025","journal-title":"Am. J. Hematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discovery"},{"key":"B45","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death & Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to Venetoclax-Based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Monocytic Subclones Confer Resist. Venetoclax-Based Ther. Acute Myeloid Leukemia Patients. Cancer Discov."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Medicine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long\u2010term follow\u2010up of VIALE\u2010A: venetoclax and azacitidine in chemotherapy\u2010ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. Journal Hematology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1182\/blood-2025-3493","article-title":"Prospective clinical validation of MAC-scoring as an affordable, real-time biomarker for HMA\/venetoclax response in AML","volume":"146","author":"Renders","year":"2025","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2024024245","article-title":"TP53-mutated acute myeloid leukemia: how can we improve outcomes?","volume":"145","author":"Sallman","year":"2025","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3390\/hemato2040051","article-title":"The current understanding of and treatment paradigm for newly-diagnosed TP53-mutated acute myeloid leukemia","volume":"2","author":"Shallis","year":"2021","journal-title":"Hemato"},{"key":"B55","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/cncr.34535","article-title":"TP53\u2010altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity","volume":"129","author":"Shallis","year":"","journal-title":"Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e767","DOI":"10.1016\/S2352-3026(23)00159-X","article-title":"Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts","volume":"10","author":"Shallis","year":"","journal-title":"Lancet Haematol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute myeloid leukemia: 2025 update on diagnosis, risk\u2010stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.3390\/cancers15194816","article-title":"TP53 mutation in acute myeloid leukemia: an old foe revisited","volume":"15","author":"Shin","year":"2023","journal-title":"Cancers"},{"key":"B59","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Medicine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat. Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncology"},{"key":"B62","first-page":"481","volume-title":"Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia","author":"Sutherland","year":"2009"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t (14; 18) chromosome translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1182\/blood-2024-193274","article-title":"Oral decitabine\/cedazuridine in patients with MDS and TP53 mutations: a propensity score matching analysis from the phase II and III trials","volume":"144","author":"Urrutia","year":"2024","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/blood-2024-201311","article-title":"Multi-omic analyses of TP53-Mutated acute Myeloid leukemia identify prognostic metabolic signatures","volume":"144","author":"Vadakekolathu","year":"2024","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/blood-2023-189340","article-title":"Targeting venetoclax resistance in TP53-Mutated acute myeloid leukemia","volume":"142","author":"V\u00e4nttinen","year":"2023","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1002\/cncr.33675","article-title":"Outcomes in patients with newly diagnosed TP53\u2010mutated acute myeloid leukemia with or without venetoclax\u2010based therapy","volume":"127","author":"Venugopal","year":"2021","journal-title":"Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduction Targeted Therapy"},{"key":"B69","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrm2147","article-title":"p53 in health and disease","volume":"8","author":"Vousden","year":"2007","journal-title":"Nat. Reviews Mol. Cell Biology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discovery"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","article-title":"Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients","volume":"15","author":"Willekens","year":"2025","journal-title":"Blood Cancer Journal"},{"key":"B73","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-024-00579-9","article-title":"p53 biology and reactivation for improved therapy in MDS and AML","volume":"12","author":"Zawacka","year":"2024","journal-title":"Biomark. Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1748-717X-4-47","article-title":"AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK\/JNK pathway and enhances radiation-induced apoptosis","volume":"4","author":"Zerp","year":"2009","journal-title":"Radiat. Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduction Targeted Therapy"},{"key":"B76","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1067\/mai.2001.117819","article-title":"How cells die: apoptosis pathways","volume":"108","author":"Zimmermann","year":"2001","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1779094\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:56:19Z","timestamp":1773816979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1779094\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":76,"alternative-id":["10.3389\/fcell.2026.1779094"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1779094","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1779094"}}